マイトマイシンC
WordNet
- the 3rd letter of the Roman alphabet (同)c
- (music) the keynote of the scale of C major
- a general-purpose programing language closely associated with the UNIX operating system
- a complex of antibiotic substances obtained from a streptomyces bacterium; one form (trade name Mutamycin) shows promise as an anticancer drug (同)Mutamycin
PrepTutorEJDIC
- carbonの化学記号
- cesiumの化学記号
- cadmiumの化学記号
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/10/15 03:44:57」(JST)
[Wiki en表示]
Mitomycin C
|
|
Systematic (IUPAC) name |
{11-Amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl}methyl carbamate
|
Clinical data |
Pregnancy
category |
- AU: D
- US: D (Evidence of risk)
|
Legal status |
Legal status |
- UK: POM (Prescription only)
- US: ℞-only
|
Pharmacokinetic data |
Metabolism |
Hepatic |
Biological half-life |
8–48 min |
Identifiers |
CAS Number |
50-07-7 |
PubChem |
CID 5746 |
IUPHAR/BPS |
7089 |
DrugBank |
DB00305 |
ChemSpider |
5544 |
UNII |
50SG953SK6 |
KEGG |
C06681 |
ChEBI |
CHEBI:27504 |
ChEMBL |
CHEMBL105 |
Chemical data |
Formula |
C=15 |
Molar mass |
154.17 g·mol−1 |
SMILES
-
CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
|
InChI
-
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
Y
-
Key:NWIBSHFKIJFRCO-WUDYKRTCSA-N
|
Physical data |
Melting point |
360 °C (680 °F) |
Solubility in water |
8.43 g L−1 mg/mL (20 °C) |
Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage.
Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery.[1] The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue.
Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'.[2] Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation.[3] Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery.
References
- ^ Kersey JP, Vivian AJ (Jul–Sep 2008). "Mitomycin and amniotic membrane: a new method of reducing adhesions and fibrosis in strabismus surgery". Strabismus. pp. 116–118. doi:10.1080/09273970802405493. PMID 18788060.
- ^ Tomasz, Maria (September 1995). "Mitomycin C: small, fast and deadly (but very selective).". Chemistry and Biology. 2 (9): 575–579. doi:10.1016/1074-5521(95)90120-5. PMID 9383461.
- ^ Renault, J.; Baron, M; Mailliet, P.; et al. (1981). "Heterocyclic quinones 2. Quinoxaline-5,6-(and 5-8)-diones - Potential antitumoral agents". Eur. J. Med. Chem. 16 (6): 545–550.
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Modification of cellular DNA by synthetic aziridinomitosenes.
- Mallory CM1, Carfi RP2, Moon S3, Cornell KA4, Warner DL5.
- Bioorganic & medicinal chemistry.Bioorg Med Chem.2015 Dec 1;23(23):7378-85. doi: 10.1016/j.bmc.2015.10.028. Epub 2015 Oct 21.
- Two synthetic aziridinomitosenes (AZMs), Me-AZM and H-AZM, structurally related to mitomycin C (MC) were evaluated for their anticancer activity against six cancer cell lines (HeLa, Jurkat, T47D, HepG2, HL-60, and HuT-78) and tested for their DNA-modifying abilities in Jurkat cells. Cytotoxicity ass
- PMID 26541587
- Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
- Yates A1, Carroll S2, Kneebone A3, Tse R2, Horvath L4, Byrne C5, Solomon M5, Hruby G3.
- Clinical oncology (Royal College of Radiologists (Great Britain)).Clin Oncol (R Coll Radiol).2015 Dec;27(12):700-7. doi: 10.1016/j.clon.2015.08.006. Epub 2015 Sep 14.
- AIMS: Modern chemoradiotherapy used for the treatment of anal cancer has significant acute toxicity. Intensity-modulated radiotherapy (IMRT) may reduce these side-effects. We report our experience implementing IMRT with simultaneous boost at the Sydney Cancer Centre and Royal North Shore Hospital.MA
- PMID 26382849
- The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus.
- Downing A1, Morris EJ2, Aravani A2, Finan PJ3, Lawton S4, Thomas JD5, Sebag-Montefiore D6.
- Clinical oncology (Royal College of Radiologists (Great Britain)).Clin Oncol (R Coll Radiol).2015 Dec;27(12):708-12. doi: 10.1016/j.clon.2015.06.019. Epub 2015 Jul 15.
- Between 1987 and 1994, three randomised phase III trials showed that chemoradiotherapy with mitomycin C and 5-fluorouracil was superior to radiotherapy alone (ACT1, European Organization for Research and Treatment of Cancer) or radiotherapy with 5-fluorouracil (Radiation Therapy Oncology Group 87-04
- PMID 26188917
Japanese Journal
- マイトマイシンC併用初発翼状片手術前後での自発性瞬目の変化の検討 (特集 第67回日本臨床眼科学会講演集(7))
- 筋層非浸潤性膀胱癌に対する再発予防目的Mitomycin C膀胱内注入療法の検討
- 大杉 治之,北村 悠樹,眞鍋 由美 [他]
- 泌尿器科紀要 = Acta urologica Japonica 60(8), 375-379, 2014-08
- NAID 40020166152
- 筋層非浸潤性膀胱癌に対する再発予防目的Mitomycin C膀胱内注入療法の検討
- 大杉 治之,北村 悠樹,眞鍋 由美,増田 憲彦,伊東 晴喜,三品 睦輝,奥野 博
- 泌尿器科紀要 = Acta urologica Japonica 60(8), 375-379, 2014-08
- … Mitomycin C (MMC) is commonly used as adjuvant treatment for NMIBC. …
- NAID 120005468368
Related Links
- This is an international website for Mitomycin-C Kyowa. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located.
- マイトマイシンC(抗がん性抗生物質) 商品名(製造・販売会社) マイトマイシン(協和発酵) 抗がん性抗生物質です。アルキル化剤と同じようにDNAの分裂阻止や、活性酸素によるDNA鎖切断などによってDNAの複製を阻害し、抗がん作用 ...
Related Pictures
![Mitomycin C (CAS 50-07-7)](https://1mg.info/0/8/2/0211.jpg)
![Mitomycin-c Mitomycin 40 Mg Injection](https://1mg.info/0/8/2/0212.jpg)
![抗がん剤の種類と副作用](https://1mg.info/0/8/2/0213.jpg)
![Bột pha tiêm Mitomycin-C Kyowa](https://1mg.info/0/8/2/0214.jpg)
![Mitomycin](https://1mg.info/0/8/2/0215.jpg)
★リンクテーブル★
[★]
- 英
- mitomycin C mitomycin-C, MMC
- 商
- マイトマイシン
- 関
添付文書
- http://www.info.pmda.go.jp/go/pack/4231400D2038_1_07/4231400D2038_1_07?view=body
-mitomycin C
- 同
- MMC
[★]
- 英
- mitomycin
- ラ
- mitomycinum
- 同
- Mutamycin???
- 同
- マイトマイシンC???
- 関
- マイトマイシンC mitomycin C MMC
[★]
[★]
[★]
セシウム, caesium, cesium
[★]
カドミウム
- 関
- cadmium
[★]